Fortress Biotech’s Subsidiary Merges with Sun Pharma

An announcement from Fortress Biotech ( (FBIO) ) is now available.

On May 30, 2025, Fortress Biotech‘s subsidiary, Checkpoint Therapeutics, merged with Sun Pharmaceutical Industries, resulting in Checkpoint becoming a wholly-owned subsidiary of Sun Pharma and deconsolidated from Fortress. This transaction provides Fortress with $28 million in cash and potential additional earnings through a regulatory milestone and royalty payments, impacting its financial structure and future revenue streams.

The most recent analyst rating on (FBIO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.

Spark’s Take on FBIO Stock

According to Spark, TipRanks’ AI Analyst, FBIO is a Neutral.

The overall score is predominantly influenced by the company’s poor financial performance, characterized by declining revenues and persistent losses, which pose significant risks. While there is some positive sentiment from the earnings call and moderate technical momentum, these do not sufficiently offset the financial challenges.

To see Spark’s full report on FBIO stock, click here.

More about Fortress Biotech

Fortress Biotech operates in the biopharmaceutical industry, focusing on the development and commercialization of novel pharmaceutical products. The company is involved in various therapeutic areas and collaborates with multiple subsidiaries and partners to advance its pipeline and market presence.

Average Trading Volume: 240,898

Technical Sentiment Signal: Sell

Current Market Cap: $54.41M

See more data about FBIO stock on TipRanks’ Stock Analysis page.